47 U.S. lawmakers have disclosed 181 GlaxoSmithKline PLC trades under the STOCK Act — 144 buys and 35 sells between 2012 and 2025. Congress has been net buyers of GSK, and their disclosed buys are up 31.9% versus the latest close.
*Notional-weighted price return on lawmakers' disclosed buys of GSK, marked to the latest close — per-share (share counts aren't disclosed).
| Date | Member | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2019-10-11 | Virginia Foxx | BUY | $1K–$15K | $42.18 | $50.45 2026-08-13 | +19.6% |
| 2019-07-30 | RICHARD M BURR | BUY | $1K–$15K | $41.82 | $50.45 2026-08-13 | +20.6% |
| 2019-07-12 | Virginia Foxx | BUY | $1K–$15K | $40.42 | $50.45 2026-08-13 | +24.8% |
| 2019-04-30 | David P. Roe | BUY | $1K–$15K | $41.13 | $50.45 2026-08-13 | +22.7% |
| 2019-04-26 | F. James Sensenbrenner Jr. | BUY | $1K–$15K | $40.40 | $50.45 2026-08-13 | +24.9% |
| 2019-04-12 | Virginia Foxx | BUY | $1K–$15K | $40.60 | $50.45 2026-08-13 | +24.3% |
| 2019-01-10 | Virginia Foxx | BUY | $1K–$15K | $39.36 | $50.45 2026-08-13 | +28.2% |
| 2018-12-11 | Virginia Foxx | BUY | $15K–$50K | $37.36 | $50.45 2026-08-13 | +35.0% |
| 2018-11-27 | Fred Upton | SELL | $1K–$15K | $40.41 | $50.45 2026-08-13 | -25.0% rt |
| 2018-11-27 | Fred Upton | BUY | $1K–$15K | $40.41 | $50.45 2026-08-13 | +24.9% |
| 2018-10-09 | Virginia Foxx | BUY | $1K–$15K | $39.47 | $50.45 2026-08-13 | +27.8% |
| 2018-09-09 | Roger W. Marshall | SELL | $1K–$15K | $39.60 | $50.45 2026-08-13 | 0.0% rt |
| 2018-09-09 | Roger W. Marshall | BUY | $1K–$15K | $39.60 | $50.45 2026-08-13 | +27.4% |
| 2018-08-30 | Zoe Lofgren | SELL | $1K–$15K | $41.24 | $50.45 2026-08-13 | -22.3% exit |
| 2018-08-20 | James B. Renacci | BUY | $1K–$15K | $41.33 | $50.45 2026-08-13 | +22.1% |
| 2018-06-28 | Steve Womack | SELL | $1K–$15K | $39.57 | $50.45 2026-08-13 | -27.5% exit |
| 2018-05-01 | John K. Delaney | BUY | $1K–$15K | $40.04 | $50.45 2026-08-13 | +26.0% |
| 2018-04-12 | Virginia Foxx | BUY | $1K–$15K | $40.62 | $50.45 2026-08-13 | +24.2% |
| 2018-04-02 | George Holding | BUY | $1K–$15K | $38.85 | $50.45 2026-08-13 | +29.9% |
| 2018-03-08 | Mike Kelly | BUY | $1K–$15K | $37.52 | $50.45 2026-08-13 | +34.5% |
| 2018-01-22 | John K. Delaney | BUY | $1K–$15K | $38.56 | $50.45 2026-08-13 | +30.8% |
| 2018-01-16 | Fred Upton | BUY | $1K–$15K | $37.92 | $50.45 2026-08-13 | +33.0% |
| 2018-01-12 | James B. Renacci | BUY | $1K–$15K | $37.50 | $50.45 2026-08-13 | +34.5% |
| 2018-01-10 | James B. Renacci | BUY | $1K–$15K | $36.40 | $50.45 2026-08-13 | +38.6% |
| 2018-01-09 | James B. Renacci | BUY | $1K–$15K | $36.95 | $50.45 2026-08-13 | +36.5% |
| 2018-01-03 | Katherine M. Clark | SELL | $1K–$15K | $36.79 | $50.45 2026-08-13 | -37.1% exit |
| 2017-12-04 | Fred Upton | BUY | $1K–$15K | $35.00 | $50.45 2026-08-13 | +44.1% |
| 2017-11-13 | James B. Renacci | BUY | $1K–$15K | $35.09 | $50.45 2026-08-13 | +43.8% |
| 2017-11-10 | James B. Renacci | BUY | $1K–$15K | $35.30 | $50.45 2026-08-13 | +42.9% |
| 2017-11-07 | Kenneth R. Buck | SELL | $1K–$15K | $35.82 | $50.45 2026-08-13 | -40.8% exit |
| 2017-11-02 | David P. Roe | BUY | $1K–$15K | $35.95 | $50.45 2026-08-13 | +40.3% |
| 2017-10-25 | Virginia Foxx | BUY | $1K–$15K | $38.19 | $50.45 2026-08-13 | +32.1% |
| 2017-10-25 | Pete Sessions | BUY | $1K–$15K | $38.19 | $50.45 2026-08-13 | +32.1% |
| 2017-10-24 | Virginia Foxx | BUY | $1K–$15K | $40.48 | $50.45 2026-08-13 | +24.6% |
| 2017-08-31 | Pete Sessions | SELL | $1K–$15K | $40.23 | $50.45 2026-08-13 | +7.5% rt |
| 2017-08-04 | Virginia Foxx | BUY | $15K–$50K | $40.53 | $50.45 2026-08-13 | +24.5% |
| 2017-07-20 | James B. Renacci | BUY | $1K–$15K | $42.77 | $50.45 2026-08-13 | +18.0% |
| 2017-06-15 | Patty Murray | SELL | $1K–$15K | $43.43 | $50.45 2026-08-13 | +2.8% rt |
| 2017-06-14 | Rohit Khanna | BUY | $1K–$15K | $43.62 | $50.45 2026-08-13 | +15.7% |
| 2017-05-18 | John K. Delaney | BUY | $1K–$15K | $43.24 | $50.45 2026-08-13 | +16.7% |
| 2017-05-04 | James B. Renacci | BUY | $1K–$15K | $41.75 | $50.45 2026-08-13 | +20.8% |
| 2017-05-04 | Rohit Khanna | exchange | $1K–$15K | $41.75 | $50.45 2026-08-13 | +20.8% |
| 2017-03-16 | Patty Murray | BUY | $1K–$15K | $42.26 | $50.45 2026-08-13 | +19.4% |
| 2017-02-27 | RICHARD BLUMENTHAL | BUY | $1K–$15K | $41.57 | $50.45 2026-08-13 | +21.4% |
| 2017-02-22 | Charlie Joseph Crist | SELL | $50K–$100K | $41.03 | $50.45 2026-08-13 | -23.0% exit |
| 2017-02-17 | RICHARD M BURR | BUY | $1K–$15K | $41.34 | $50.45 2026-08-13 | +22.0% |
| 2016-12-27 | Kurt Schrader | BUY | $1K–$15K | $38.28 | $50.45 2026-08-13 | +31.8% |
| 2016-12-14 | Kenny Marchant | BUY | $1K–$15K | $37.96 | $50.45 2026-08-13 | +32.9% |
| 2016-12-01 | Kurt Schrader | BUY | $1K–$15K | $37.43 | $50.45 2026-08-13 | +34.8% |
| 2016-12-01 | Pete Sessions | BUY | $1K–$15K | $37.43 | $50.45 2026-08-13 | +34.8% |
Return: buys marked to the latest close (open); sells tagged rt are realized round-trips vs a prior disclosed buy; exit = timing (stock move after the sale, seller's perspective).
47 members of the U.S. House and Senate have disclosed GlaxoSmithKline PLC transactions under the STOCK Act — 144 purchases and 35 sales. The full member-by-member breakdown, with dates and dollar ranges, is in the table above.
No member of Congress has disclosed a GSK purchase in the last 90 days. STOCK Act filings lag the trade by up to 45 days, so newer buys may still be pending disclosure.
Notional-weighted, lawmakers' disclosed GSK buys are up 31.9% versus the latest close of $50.45. Each trade's own return — and realized round-trips on matched sells — is in the Return column.
Yes. Under the 2012 STOCK Act, members of Congress may buy and sell individual stocks but must publicly disclose each transaction within 45 days. Bargo surfaces those filings so you can see who traded GSK and how it performed.